As an oral thrombopoietin receptor agonist, Doptelet (Avatrombopag) provides an innovative solution for the preoperative management of patients with thrombocytopenia associated with chronic liver disease.

Indications for Doptelet (Avatrombopag)

Main Indications

Doptelet is clearly indicated for the treatment of perioperative thrombocytopenia in adult patients with chronic liver disease.

Target population: Adult patients diagnosed with chronic liver disease who are scheduled to undergo invasive procedures (such as surgical operations or dental treatments).

Treatment objective: To increase the platelet count to a safe threshold and reduce the risk of intraoperative and postoperative bleeding. It should be noted that this drug is not intended to fully restore the platelet count to a normal level.

Key limitation: It is not applicable to pediatric patients, as its safety and efficacy have not been established in the pediatric population.

Dosage Form, Strength, and Properties of Doptelet (Avatrombopag)

Dosage Form and Strength

Dosage form: Round, biconvex, yellow film-coated tablets, imprinted with "AVA" and "20".

Strength: Each tablet contains 20 mg of avatrombopag (equivalent to 23.6 mg of avatrombopag maleate).

Composition

Active ingredient: Avatrombopag maleate, a specific thiazole carbamoyl pyridine derivative in terms of chemical structure.

Excipients: Include core excipients such as lactose monohydrate, colloidal silicon dioxide, and crospovidone. The film coating layer is composed of polyvinyl alcohol, talc, iron oxide yellow, etc.

Physicochemical Properties

Solubility: Almost insoluble in the pH range of 1-11, and its absorption depends on the gastrointestinal environment.

Pharmacokinetics: The peak plasma concentration is reached 5-6 hours after oral administration, with an elimination half-life of approximately 19 hours. It is mainly metabolized by CYP2C9 and CYP3A4.

Storage Specifications for Doptelet (Avatrombopag)

Temperature Control

It is recommended to store at a standard room temperature of 20°C to 25°C (68°F to 77°F).

Short-term storage within a fluctuating temperature range of 15°C to 30°C (59°F to 86°F) is allowed.

Packaging Requirements

The original packaging must be retained to prevent uncoated tablets from being exposed to moisture or strong light.

The aluminum-plastic blister packaging can effectively prevent moisture; unused tablets after unpacking should be put back into the original packaging and sealed.

Special Precautions

Store out of the reach of children.

Expired or damaged tablets should be disposed of in accordance with medical waste regulations.